ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Cardiovascular and Smooth Muscle Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1544121
What is the best clinical management strategies for cardiomyopathy? an umbrella review of systematic review and meta-analysis
Provisionally accepted
- The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background To summarize and evaluate the quality of evidence regarding effectiveness and safety of different interventions for patients with cardiomyopathy from published meta-analyses via umbrella review.The literature was searched via PubMed, Embase, Web of Science, and the Cochrane. Two reviewers evaluated the methodological quality of the included articles through the AMSTAR score. In addition, according to GRADE, evidence of each outcome was evaluated and graded as "high", "moderate", "low" or "very low" quality to draw conclusions. Additionally, each evidence of outcome was classified into 4 categories (Class I to IV and Non significant) .Results High-quality evidence suggested that for patients with cardiomyopathy, stem cell treatment could significantly improve left ventricular ejection fraction (LVEF), left ventricular ejection volume, 6-minute walk distance(6-MWD) and New York Heart Association (NYHA) functional classification. High-quality evidence also suggested that for patients with dilated cardiomyopathy (DCM), adding traditional Chinese medicines such as Qili Qiangxin Capsule (QQC), Shenmai injection (SMI), Zhigancao and Shengmai to conventional western medicine treatment could significantly improve clinical effect, LVEF, 6-WMD and reduce inflammatory indicators, left ventricular end-systolic diameter, left ventricular end-diastolic diameter (LVEDD) and heart rate. In addition, the high-quality evidence suggested that for patients with DCM, using of drugs such as atrovastatin, carvediol, thyroid hormone and L-carnitine could significantly improve LVEF, cardiac output and reduce C-Reactive Protein, systolic blood pressure, LVEDD, left ventricular end-diastolic and end-systolic volume. Furthermore, implantable cardioverter defibrillator therapy could significantly reduce sudden cardiac death.Conclusions High-quality evidences showed that cell therapy, atorvastatin, carvediol, thyroid hormone have significant improvement effects on the prognosis of cardiomyopathy. Besides, combining with traditional Chinese medicines could significantly improve the effectiveness of conventional western medicine therapy for cardiomyopathy.
Keywords: cardiomyopathy, intervention, Treatment, prognosis, Umbrella review
Received: 12 Dec 2024; Accepted: 30 Jun 2025.
Copyright: © 2025 Cheng, Wang and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Wanru Cheng, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.